Table 3.

Multivariate analysis of factors predicting pCR after NAC

Parameters	Odds ratio	95% Confidence interval	P value
Clinical T stage
T1 vs T4	5.304	2.222–12.664	< 0.001
T2 vs T4	1.808	1.065–3.067	0.028
T3 vs T4	1.216	0.648–2.282	0.541
Clinical N stage
N0 vs N2	2.434	1.201–4.933	0.014
N1 vs N2	3.344	2.196–5.090	< 0.0001
SBR grade
2/1	2.327	0.765–7.073	0.137
3/1	3.312	1.101–9.963	0.033
Subtype
HR + /HER2 + vs  HR + /HER2−	4.851	2.862–8.221	< 0.0001
HR−/HER2 + vs HR + / HER2−	8.781	5.146–14.986	< 0.0001
HR−/HER2− vs HR + /HER2−	4.868	2.722–8.706	< 0.0001

HR hormone receptor, HER-2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy, pCR pathological complete response